person · Reporting owner
Zygmont Chester Stanley III
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Chief Financial Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-17 · Grant · Acquired 208,073 · Balance 208,073 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Row 2 · 2026-08-17 · Gift · Disposed 208,073 · Balance 0 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 300,136 |
Reported balance
After 2026-08-17 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-17 · Gift · Acquired 208,073 · Balance 300,136 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. F2: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. |
| Common StockSEC Table I · non-derivative | Indirectby LLC | 2 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2 F3: Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
F2: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
F3: Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GiftCommon Stock | 208,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 3 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 300,136 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GiftCommon Stock | 208,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 2 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 208,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 1 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,073 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:31 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 13,285 | $1.10 | $14,613.50 |
DisclosureSEC source: 0001193125-26-201764 · ownership.xml · nonDerivative · entry 1 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 92,063 F1 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 22:29 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 13,100 | $1.65 | $21,615.00 |
DisclosureSEC source: 0001193125-26-039686 · ownership.xml · nonDerivative · entry 1 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 105,348 F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F4 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:17 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 78,145 | $0.90 | $70,330.50 |
DisclosureSEC source: 0001193125-26-010642 · ownership.xml · nonDerivative · entry 3 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 473,790 F1 · security: Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant. F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 16:55 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 390,614 | $1.28 | $499,985.92 |
DisclosureSEC source: 0001193125-25-260417 · ownership.xml · nonDerivative · entry 3 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 395,645 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant. F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 23:05 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 15,048 | $3.87 | $58,235.76 |
DisclosureSEC source: 0000950170-25-020104 · ownership.xml · nonDerivative · entry 3 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 15,076 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:09 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantStock Option (Right to Buy) · Derivative | 611 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013633 · doc4.xml · derivative · entry 1 Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 611 shares Expires 2032-02-25 F1 · derivative.exercise_date: The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.